European Journal of Nuclear Medicine and Molecular Imaging

Article	Citations
“Fuzzy” radiomics: the way forward for nuclear medicine imaging applications?	331
Towards molecular imaging-guided intervention theatres in oncology	233
Tumor agnostic ultrasmall nanoprobes for fluorescence-guided surgical resection in peritoneal metastasis	227
Intriguing information from recent letter and article regarding unwanted targeting of salivary glands by PSMA ligands	176
A visual whole-body tumor-burden classification based on PSMA PET/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients	160
FAPI PET/CT in infectious, inflammatory, and rheumatological diseases: “watch it like a hawk” or “one swallow does not make a summer”?	129
Melanin-targeted [18F]-PFPN PET imaging may shed light for clear cell sarcoma	117
Avid 18F-FDG uptake of benign gastric-type intraductal papillary mucinous neoplasm of the pancreas	113
Real-time diagnosis of sampled lesions in targeted biopsy of prostate Cancer using a novel tracer [64Cu] Cu-DOTA-PSMA-3Q: a pilot preclinical study	96
New horizons for the World Federation of Nuclear Medicine and Biology: achievements, partnerships, and future directions	96
[18F]Fluorocholine PET/MRI and [18F]Fluorocholine PET/CT as first- and second-line imaging in primary hyperparathyroidism – who takes the lead?	91
Cadherin-17 as a target for the immunoPET of adenocarcinoma	90
Variabilities in global DNA methylation and β-sheet richness establish spectroscopic landscapes among subtypes of pancreatic cancer	81
Assessment of [18F]PI-2620 Tau-PET Quantification via Non-Invasive Automatized Image Derived Input Function	80
Vancomycin-based tracers guiding in situ visualization of bacteria on osteosynthesis devices and surgical debridement	76
PSMA expression and PSMA PET/CT imaging in metastatic soft tissue sarcoma patients, results of a prospective study	76
Persistent lung and vascular inflammation in mild to moderate COVID-19 survivors detected by ¹⁸F-FDG PET/CT: A quantitative imaging study with implications for cardiovascular risk	75
Nuclear imaging and therapy in oncology in Poland in 2021–2022	73
FAPI PET for monitoring of rheumatological treatment in multifocal peritoneal nodular fibrosis: a case study	65
Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review	57
Correction to: Preclinical SPECT and PET: Joint EANM and ESMI procedure guideline for implementing an efficient quality control programme	56
Combination therapy of an 211At-labeled RGD peptide and immune checkpoint blockade to enhance antitumor efficacy	55
Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangli	55
Sex-specific differences in patients with differentiated thyroid carcinoma and their possible impact on survival	54
Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis	52

Deep learning–based whole-body characterization of prostate cancer lesions on [68Ga]Ga-PSMA-11 PET/CT in patients with post-prostatectomy recurrence	52
Individual-level metabolic connectivity from dynamic [18F]FDG PET reveals glioma-induced impairments in brain architecture and offers novel insights beyond the SUVR clinical standard	52
Long-term impact of myocardial inflammation on quantitative myocardial perfusion—a descriptive PET/MR myocarditis study	50
Brain perfusion estimation by Tikhonov model-free deconvolution in a long axial field of view PET/CT scanner exploring five different PET tracers	49
[18F]FDG PET/MR to assess disease extension and inflammation in children and young adults with primary ciliary dyskinesia	49
Enhancing interpretability of AI with radiomics-based deep neural network: proof of concept in the classification of Parkinsonian syndromes with 18F-FDG PET imaging	49
Dynamic frame-by-frame motion correction for 18F-flurpiridaz PET-MPI using convolution neural network	49
Prospective clinical study of sentinel node detection in bladder cancer using a hybrid tracer – Towards replacement of pelvic lymph node dissection in cases with sentinel node visualization on SPECT/C	49
[68Ga]Ga-FAPI versus [18F]FDG PET/CT in the evaluation of Langerhans cell histiocytosis	49
Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617	49
The feasibility of quantitative assessment of dynamic 18F-fluorodeoxyglucose PET in Takayasu’s arteritis: a pilot study	48
First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2	48
Prospective pilot study with [89Zr]Zr-girentuximab PET/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE)	48
Cinematic rendering of [18F]FDG-PET/MR	48
Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group	47
Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus	47
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer	47
Simultaneous high-resolution whole-brain MR spectroscopy and [18F]FDG PET for temporal lobe epilepsy	47
Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma	46
Non-invasive visualization of liver fibrosis with [68Ga]Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation	46
TMTV-Net: fully automated total metabolic tumor volume segmentation in lymphoma PET/CT images — a multi-center generalizability analysis	45
Preclinical development of [18F]TAAR1-2203 as a PET radioligand for imaging TAAR1 expression and receptor occupancy	45
Seasonal variation in D2/3 dopamine receptor availability in the human brain	44
Robust and generalizable artificial intelligence for multi-organ segmentation in ultra-low-dose total-body PET imaging: a multi-center and cross-tracer study	44
Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation	44
Abdelhamid H. Elgazzar, Synopsis of Pathophysiology in Nuclear Medicine, Second Edition	43
68Ga-FAPI and 18F-FDG PET/CT for predicting pathologic response and progression-free survival in locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy	43
Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial	43
Tracking macrophages by direct and indirect 89Zr PET imaging	43
Updated practice guideline for dual-energy X-ray absorptiometry (DXA)	43
Diffusely increased breast uptake of [18F]AlF-NOTA-FAPI-04 related to menstrual status in a patient with papillary thyroid cancer	42
Multi-modality deep learning-based [68Ga]Ga-DOTA-FAPI-04 PET polar map generation: potential value in detecting reactive fibrosis after myocardial infarction	42
Sentinel lymph node detection in thyroid carcinoma using [68Ga]Ga-tilmanocept PET/CT: a proof-of-concept study	42
Bilateral intense [68 Ga]Ga-PSMA‑11 uptake in cyproterone acetate induced gynecomastia	42
Lisa Bodei, Jason S. Lewis, Brian M. Zeglis (Editors): Radiopharmaceutical Therapy	42
Abnormal localized [18F]FDG accumulation in a Hoffman 3D brain phantom caused by Pseudomonas aeruginosa and Stenotrophomonas maltophilia	42
[68Ga]Ga-Pentixafor PET/CT for Durie-Salmon PLUS staging and risk stratification in newly diagnosed multiple myeloma	41
Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer	41
Molecular radiotherapy for adult type metastatic neuroendocrine tumours in children	41
Parkinson’s Disease-Related pattern in isolated REM sleep behaviour disorder as a prodromal progression marker: 8-Year Follow-Up changes assessed at three time points	39
Assessment of cerebral drug occupancy in humans using a single PET-scan: A [11C]UCB-J PET study	39
[18F]-mFBG imaging for COVID-19-induced cardiac sympathetic innervation impairment	39
Preclinical and first‑in‑human evaluation of [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P PET imaging to assess tumor PD-L1 expression	39
An artificial intelligence-driven image quality assessment system for whole-body [18F]FDG PET/CT	39
[68Ga]Ga-P16-093 PET/CT in newly diagnosed prostate cancer: Histopathological validation and comparison with [68Ga]Ga-PSMA-11	39
Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside	39
Diagnostic accuracy of PSMA-targeted radioguided surgery in prostate cancer at multiple anatomical levels: a systematic review and meta-analysis	39
About ESTMABLE2: non-inferiority doesn’t equal better	38
Intense [68Ga]Ga-FAPI-04 uptake of pancreatic microcystic serous cystadenoma mimicking malignancy	38
Moganshan international consensus on further strengthening global scientific collaboration in the field of molecular imaging	38

Distinguishing benign lesions from malignant ones using FAPI-based tracers: will we need to bid farewell to dual-time points imaging?	37
PSMA-targeted radioligand therapy with [177Lu]Lu-LNC1011 for metastatic castration-resistant prostate cancer: a pilot study	37
Advancements in non-invasive visualization of the immune checkpoint TIGIT: a systematic review	37
Correction to: A bis-boron boramino acid PET tracer for brain tumor diagnosis	37
Increased incidence of primary metastatic prostate cancer in the era of PSMA PET/CT: a population-based analysis	37
A cutting-edge technology for the future of nuclear medicine	37
Brachytherapy at the nanoscale with protein functionalized and intrinsically radiolabeled [169Yb]Yb2O3 nanoseeds	37
Correction to: Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993	37
Preclinical evaluation and pilot clinical study of [68Ga]Ga-NOTA-H006 for non-invasive PET imaging of 5T4 oncofetal antigen	36
Promise of hypoxia-targeted tracers in metastatic lymph node imaging	36
Validation of simplified uptake measures against dynamic Patlak Ki for quantification of lesional 89Zr-Immuno-PET antibody uptake	36
Interpretable multimodal deep learning model for predicting post-surgical international society of urological pathology grade in primary prostate cancer	36
[68Ga]Ga-DOTA-FAPI-04 PET/CT depicts metastases from medullary thyroid cancer that [68Ga]Ga-DOTATOC PET/CT missed	36
Identifying and navigating bottlenecks in the translation of novel radiopharmaceuticals: a perspective	36
Comparative assessment of radiation therapy–induced vasculitis using [18F]FDG-PET/CT in patients with non-small cell lung cancer treated with proton versus photon radiotherapy	36
Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993	36
A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [68Ga]Ga-PSMA-11 total-body PET/CT imaging	36
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin’s lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgk	35
Imaging biomarkers of cortical neurodegeneration underlying cognitive impairment in Parkinson’s disease	35
Ternary classification prediction and heterogeneity quantification for HER2-Zero, -low, and -positive in breast cancer using HER2-targeted PET/CT imaging	35
Development of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography	35
Comparison of two hybrid sentinel node tracers: indocyanine green (ICG)-99mTc-nanocolloid vs. ICG-99mTc-nanoscan from a nuclear medicine and surgical perspective	35
Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study	35
Atypical [18F]FDG avidity in ALK-positive anaplastic large cell lymphoma: diagnostic and monitoring potential of [18F]FAPI PET/CT	34
A hybrid radioactive and fluorescence approach is more than the sum of its parts; outcome of a phase II randomized sentinel node trial in prostate cancer patients	34
Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [68Ga]Ga-PSMA-11 PET scans of primary prostate cancer	34
STING-targeted PET tracer for early assessment of tumor immunogenicity in colorectal cancer after chemotherapy	34
A distinctive “Shotgun-like” 18F-FDG PET uptake pattern in disseminated cutaneous sarcoidosis responding to TNFα inhibitors	34
Synthesis, preclinical evaluation, and clinical translation of [68Ga]Ga-Asp2-JR11, a SSTR2 antagonist for PET imaging of neuroendocrine neoplasms	34
Guiding principles on the education and practice of theranostics	33
[68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors	33
Intraoperative molecular imaging of colorectal lung metastases with SGM-101: a feasibility study	33
PET imaging of new target CDK19 in prostate cancer	33
Impact of extended [177Lu] Lu-PSMA-617 therapy on absorbed kidney dose and CKD-EPI values: how long can therapy be safely continued?	33
Exploratory evaluation of early 68Ga-FAPI-46 PET/CT volume-based parameters in systemic sclerosis-associated interstitial lung disease	33
Differential Vascular Response to Corticosteroid Therapy in Takayasu Arteritis Revealed by Serial FDG-PET Imaging	33
Reply to Vaz et al., Editorial Commentary: Should “Heterogeneous response” be considered as new category for assessing treatment response in patients with breast cancer?	33
Development of STING probes and visualization of STING in multiple tumor types	33
Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)	33
Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment del	32
Forearm metastasis as solitary manifestation of recurrent prostate cancer: A challenge for standard PSMA PET imaging protocol	32
Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas	32
Prognostic role of metabolic parameters (MTV and TLG) of staging PET/CT in the pediatric population with Hodgkin’s lymphoma: an open discussion	32
Distinct metabolic patterns of neuropsychiatric systemic lupus erythematosus on hierarchical cluster analysis	32
Molecular imaging: The bridge from human phenome to personalized precision medicine	32
Radioembolization of hepatocellular carcinoma with 90Y glass microspheres: an earlier administration day unexpectedly improves tumour control probability	32
Bone marrow scintigraphy as a prognostic marker of overall survival in mCRPC patients treated with Radium-223 dichloride	31
Pre-operative dual-time-point [18F]FET PET differentiates CDKN2A/B loss and PIK3CA mutation status in adult-type diffuse glioma: a single-center prospective study	31
Correction to: Deep learning for improving PET/CT attenuation correction by elastic registration of anatomical data	31
[99mTc]Tc-sestamibi SPECT/CT for the diagnosis of kidney tumours: a multi-centre feasibility study (MULTI-MIBI Study)	31
Development and characterisation of [18F]TTDP, a novel T cell immunoglobulin and ITIM domain tracer, in humanised mice and non-human primates	31
Correction to: [18F]FDG brain PET findings in CLIPPERS at diagnosis and therapeutic follow-up	31
Radiofrequency ablation for autonomously functioning nodules as treatment for hyperthyroidism: subgroup analysis of toxic adenoma and multinodular goitre and predictors for treatment success	31
Pre-symptomatic scintigraphic and genetic cascade screening in cardiac transthyretin amyloidosis	31
European guidelines update on PSMA PET/CT for prostate cancer staging—snap back to reality	30
First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy	30
Association of PET vascular activity score with Takayasu’s arteritis angiographic progression	30
Classification of 18F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth	30
The first international network symposium on artificial intelligence and informatics in nuclear medicine: “The bright future of nuclear medicine is illuminated by artificial intelligence”	30
The diagnostic performance of [18F]Florbetazine in Alzheimer’s disease: a head-to-head comparison to [11C]PiB and [18F]Florbetapir	30
Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga]Ga-PSMA-11 PET images	30
Comparative analysis of [18F]F-FAPI PET/CT, [18F]F-FDG PET/CT and magnetization transfer MR imaging to detect intestinal fibrosis in Crohn’s disease: A prospective animal model and human cohort study	30
A comparative study of [68Ga]Ga-FAPI-04 PET/MR and [18F]FDG PET/CT in the diagnostic accuracy and resectability prediction of ovarian cancer	30
Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging	30
Disrupted gut microecology after high-dose 131I therapy and radioprotective effects of arachidonic acid supplementation	29
Comparison of the diagnostic value of [68 Ga]Ga-FAPI-04 PET/MR and [18F]FDG PET/CT in patients with T stage ≤ 2a2 uterine cervical cancer: a prospective study	29
Near-infrared II theranostic agents for the diagnosis and treatment of Alzheimer’s disease	29
Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma	29
[177Lu]Lu-FAP-2286 therapy in ovarian neuroendocrine carcinoma: a promising theranostic approach	29
First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm	29
Intelligent ultrafast total-body PET for sedation-free pediatric [18F]FDG imaging	29
Identification of a CEACAM5 targeted nanobody for positron emission tomography imaging and near-infrared fluorescence imaging of colorectal cancer	29
Comparison of mCRPC [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting	28
¹⁸F-AlF-NOTA-octreotide PET/CT in high-grade G3 neuroendocrine tumors and neuroendocrine carcinomas: diagnostic performance and complementarity with ¹⁸F-FDG PET/CT	28
Quantitative 18F-FDG PET/CT Model for predicting pathological complete response to neoadjuvant immunochemotherapy in NSCLC: comparison with RECIST 1.1 and PERCIST	28
Visual grading for noninvasive assessment of transthyretin-related cardiomyopathy with bone scintigraphy: time for moving forward?	28
Commentary to “[68 Ga]Ga-FAPI-04 PET/CT on assessing Crohn’s disease intestinal lesions” by Chen and colleagues	28
Hypermetabolic pulmonary lesions detection and diagnosis based on PET/CT imaging and deep learning models	28
Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication	27
Clinical added value of LAFOV PET/CT in patients undergoing same-day [18 F]FDG SAFOV PET/CT scans: an initial experience report and explorative study	27

Machine learning predictive performance evaluation of conventional and fuzzy radiomics in clinical cancer imaging cohorts	27
Extended nodal radiotherapy for prostate cancer relapse guided with [11C]-choline PET/CT: ten-year results in patients enrolled in a prospective trial	27
The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer	27
A rationally designed nuclei-targeting FAPI 04-based molecular probe with enhanced tumor uptake for PET/CT and fluorescence imaging	27
Longitudinal renal function following [¹⁷⁷Lu]Lu-PSMA I&T in metastatic castration-resistant prostate cancer	27
Amyloid pathology related to aberrant structure-function coupling of brain networks in Alzheimer’s disease: insights from [18F]-florbetapir PET imaging	27
Size-changeable nanoprobes for the combined radiotherapy and photodynamic therapy of tumor	27
Multicentric development and evaluation of [18F]FDG PET/CT and CT radiomic models to predict regional and/or distant recurrence in early-stage non-small cell lung cancer treated by stereotactic body r	27
PET imaging utilization and trends in Germany: a comprehensive survey	27
Evaluation of long axial field-of-view (LAFOV) PET/CT for post-treatment dosimetry in Yttrium-90 radioembolization of liver tumors: a comparative study with conventional SPECT imaging	27
Assessing non-invasive quantitative methods for [18F]SynVesT-1 PET imaging of synaptic vesicle glycoprotein 2A in the rat brain	27
PET/CT with [68Ga]Ga-TEoS-DAZA for localization of a traumatic biliary leak	26
CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology	26
Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?	26
Non-invasive molecular imaging for precision diagnosis of metastatic lymph nodes: opportunities from preclinical to clinical applications	26
Quantitative dual-tracer PET/CT biomarkers correlate concordant lesion uptake with PSMA-RLT outcomes in mCRPC: a dual-center study	26
Comparisons of treatment performance and therapy sequences in neuroendocrine neoplasms using progression-free survival ratios	26
Targeted alpha therapy: a comprehensive analysis of the biological effects from “local-regional-systemic” dimensions	26
Impact of Tafamidis on [99mTc]Tc-pyrophosphate Scintigraphy in Ala97Ser Hereditary Transthyretin amyloid cardiomyopathy: significant initial reduction with stable Long-Term effects	25
Collection on molecular imaging in cardiac amyloidosis	25
PET imaging of animal models with depressive-like phenotypes	25
Zirconium-89-based PSMA PET/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA ≤ 0.2 ng/mL: A feasibility study	25
Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study	25
The eye-black sign of lower eyelids related to R-CHOP therapy: a rare imaging pitfall	25
Beyond 68Ga-labeled somatostatin analogues: is it time to say goodbye to [68Ga]DOTA-conjugated peptides for neuroendocrine neoplasms?	25
FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis	25
Prognostic value of PSMA PET/CT-Based local staging in predicting biochemical recurrence after radical prostatectomy	25
Whole-body tumour burden on [18F]DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics	25
18F-sodium fluoride PET-CT visualizes both axial and peripheral new bone formation in psoriatic arthritis patients	25
PSMA-targeted theranostics of solid tumors: applications beyond prostate cancers	25
Exploring the value of FAP-targeted PET/CT in differentiating breast cancer molecular subtypes: a preliminary study	25
Preoperative assessment of pancreatic cancer with [68Ga]Ga-DOTA-FAPI-04 PET/MR versus [18F]-FDG PET/CT plus contrast-enhanced CT: a prospective preliminary study	24
DICOM header editing, between possibilities and regulatory bounds– 40 years of DICOM “standard”	24
Correction to: Coronavirus (COVID-19) pandemic mediated changing trends in nuclear medicine education and training: time to change and scintillate	24
PET scout: A valuable technology in pediatric 18F-FDG PET/CT imaging	24
Subendocardial quantification enhances coronary artery disease detection in 18F-flurpiridaz PET	24
Safety and efficacy of [177Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancer	24
Expert consensus on workflow of PET/CT with long axial field-of-view	24
Efficacy of combined targeted radionuclide therapy and immune checkpoint Inhibition in animal tumour models: a systematic review and meta-analysis of the literature	24
Fibroblast activation Protein-Targeted PET/CT using [18 F]FAP-2286 for the evaluation of lung cancer: A comparative study with [18 F]FDG PET/CT	24
Multimodal glyco-lipid-EBVDNA signature prognostic model for individualized risk stratification of locally advanced nasopharyngeal carcinoma	24
Comprehensive analysis of [18F]MFBG biodistribution normal patterns and variability in pediatric patients with neuroblastoma	24
Interpretive consistency of a qualitative 68Ga-PSMA PET framework for treatment response assessment in hepatocellular carcinoma: a head-to-head comparison with cross-sectional imaging	24
PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington’s disease	24
Bridging the gap to clinical translation: the advanced role of PET molecular imaging in stem cell therapy	24
Correction to: Modelling [18F]LW223 PET data using simplified imaging protocols for quantification of TSPO expression in the rat heart and brain	24
Efficiency of succinylated gelatin and amino acid infusions for kidney uptake reduction of radiolabeled αvβ6-integrin targeting peptides: considerations on clinical safety profiles	24
The value of serial [⁶⁸Ga]Ga-FAPI-04 PET/CT in predicting pathological response and evaluating therapeutic efficacy to neoadjuvant chemotherapy in breast cancer	24
Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis	24
Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study	23
Chlorin e6-loaded goat milk-derived extracellular vesicles for Cerenkov luminescence-induced photodynamic therapy	23
Fully automated spleen segmentation predicts progression-free survival in HCC patients following transarterial radioembolization	23
Neoadjuvant alpha peptide receptor radionuclide therapy for a patient with a pulmonary carcinoid	23
Pleasurable music activates cerebral µ-opioid receptors: a combined PET-fMRI study	23
Staging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AI	23
Rapid dynamic acquisition of cardiac amyloid radionuclide imaging	23
Targeting tumour surface collage with hydrogel probe: a new strategy to enhance intraoperative imaging sensitivity and stability of bladder cancer	23
Role of brain 2-[18F]fluoro-2-deoxy-D-glucose-positron-emission tomography as survival predictor in amyotrophic lateral sclerosis	23
Lymph node classification in E-PSMA reporting guidelines for PSMA-PET	22
The confounding effects of microvascular physiology on the uptake and diagnostic accuracy of [18F]fluoroethyl-tyrosine positron emission tomography in gliomas	22
Impact of deep learning denoising on kinetic modelling for low-dose dynamic PET: application to single- and dual-tracer imaging protocols	22
Remarkable response after cocktail therapy with 177Lu-PSMA and 177Lu-DOTA-IBA in the treatment of mCRPC	22
New thresholds in semi-quantitative [18F]FDG PET/CT are needed to assess large vessel vasculitis with long-axial field-of-view scanners	22
Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis	22
Multidisciplinary team interpretation performance for indeterminate bone uptake on PSMA PET during prostate cancer staging: Comparison with PROMISE criteria	22
Exploring the metabolic landscape of lung adenocarcinoma and squamous cell carcinoma: a total-body [18F]FDG PET/CT approach	22
Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology	22
Long axial field of view (LAFOV) PET-CT: implementation in static and dynamic oncological studies	22
Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020	22
In vivo methods for imaging blood–brain barrier function and dysfunction	22
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours	22
L.J. Koenig, D. Tamimi, S.E. Perschbacher, H. Demirturk. Diagnostic imaging: oral and maxillofacial. 3rd Edition	21
Positive amyloid and tau PET in an early-onset Alzheimer’s disease with a rare PSEN1 (Arg278Gly) mutation	21
[177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data	21
Complications and outcomes of radioligand therapy in patients with neuroendocrine neoplasms depending on the baseline glomerular filtration rate	21
SNMMI/EANM practice guideline vs. ETA Consensus Statement: differences and similarities in approaching differentiated thyroid cancer management—the EANM perspective	21
The role of radiographers in nuclear medicine; the link between patient and technology	21
Pigmented villonodular synovitis detected by [68Ga]Ga-FAPI-04 PET/CT	21
A. Zaheer, S.P. Raman, M.L. Rosado-de-Christenson, S. Martínez-Jiménez, S.H. Garrana, G. Fananapazir, D. Rogers, B.R. Foster: Imaging Anatomy: Chest, Abdomen, Pelvis, 3rd Edition	21
Letter to the Editor: Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer	21
The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients	21
Loss of synaptic density in nucleus basalis of meynert indicates distinct neurodegeneration in Alzheimer’s disease: the RJNB-D study	21
Total-body pediatric PET is ready for prime time	21
Connectivity based on glucose dynamics reveals exaggerated sensorimotor network coupling on subject-level in Parkinson’s disease	21
Exploring coronary microvascular function by quantitative CZT-SPECT: a small step or giant leap for INOCA patients?	21
New opportunities for dosimetric approach in patients with differentiated thyroid cancer	21
To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment	21
Comparative evaluation of a novel [18F] F-Labeled PET tracer XTR004 against [13N] ammonia in myocardial perfusion imaging for coronary artery disease	20
A network analysis of whole-body [18F]FDG PET/CT reveals glycaemia-associated reorganization of systemic metabolic coordination	20
99mTc-Tilmanocept performance for sentinel node mapping in breast cancer, melanoma, and head and neck cancer: a systematic review and meta-analysis from a European expert panel	20
Application of the long axial field-of-view PET/CT with low-dose [18F]FDG in melanoma	20
Radioligand therapy of pancreatic ductal adenocarcinoma using an αvβ6-integrin targeting 68Ga / 177Lu labeled theranostic pair	20
The effect of prednisolone and a short-term prednisolone discontinuation for the diagnostic accuracy of FDG-PET/CT in polymyalgia rheumatica—a prospective study of 101 patients	20
Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China	20
FAP inhibitors: are we really using the best method to evaluate the residence time?	20